Review Article
Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer
Table 1
Anti-angiogenic drugs approved by the United States Food and Drug Administration (2004–2012).
| Anti-VEGF drug | Approved indication |
| Bevacizumab | Metastatic colorectal cancer (with chemotherapy) | Metastatic nonsquamous non-small cell lung cancer (with chemotherapy) | Metastatic breast cancer (with chemotherapy) | Recurrent glioblastoma (monotherapy) | Metastatic renal cell carcinoma (with IFNα) | Sunitinib | Metastatic renal cell carcinoma (monotherapy) | Gastrointestinal stromal tumors (monotherapy) | Pancreatic neuroendocrine tumors (monotherapy) | Sorafenib | Metastatic renal cell carcinoma | Unresectable hepatocellular carcinoma | Pazopanib | Metastatic renal cell carcinoma | Advanced soft tissue sarcoma | Vandetanib | Advanced medullary thyroid cancer | Axitinib | Advanced renal cell carcinoma | Regoranfenib | Metastatic colorectal cancer | Aflibercept | Metastatic colorectal cancer (with chemotherapy) | Wet age-related macula degeneration | Pegaptanib | Wet age-related macula degeneration | Ranibizumab | Wet age-related macula degeneration |
|
|